
Quarterly report 2023-Q3
added 11-07-2023
Eargo Retained Earnings 2011-2026 | EAR
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -514 M | -357 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -357 M | -514 M | -436 M |
Quarterly Retained Earnings Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -579 M | -561 M | -536 M | -514 M | -471 M | -420 M | -387 M | -357 M | -311 M | -232 M | -213 M | -199 M | -199 M | -199 M | -199 M | -159 M | -159 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -159 M | -579 M | -335 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
-1.42 B | $ 13.99 | -0.36 % | $ 2.1 B | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
-307 M | $ 31.34 | 0.38 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
-54.4 M | $ 3.43 | 0.15 % | $ 119 M | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
Cognyte Software Ltd.
CGNT
|
-157 M | $ 6.92 | 4.53 % | $ 497 M | ||
|
ClearPoint Neuro
CLPT
|
-191 M | $ 13.22 | -12.8 % | $ 357 M | ||
|
Bio-Rad Laboratories
BIO
|
7.42 B | $ 269.27 | -0.06 % | $ 7.6 B | ||
|
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
2.41 B | $ 39.99 | 0.26 % | $ 5.96 K | ||
|
BioSig Technologies
BSGM
|
-255 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
5.57 B | $ 74.5 | 1.4 % | $ 110 B | ||
|
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 4.49 | -2.18 % | $ 167 M | ||
|
Electromed
ELMD
|
21.2 M | $ 24.25 | 1.38 % | $ 205 M | ||
|
CONMED Corporation
CNMD
|
589 M | $ 46.81 | 1.83 % | $ 1.45 B | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-395 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
-532 M | $ 9.32 | -8.72 % | $ 266 M | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
InMode Ltd.
INMD
|
969 M | $ 14.04 | 0.57 % | $ 907 M | ||
|
Second Sight Medical Products
EYES
|
-122 M | - | -0.97 % | $ 54.4 M | ||
|
IRadimed Corporation
IRMD
|
56.8 M | $ 101.94 | 1.43 % | $ 1.29 B | ||
|
Establishment Labs Holdings
ESTA
|
-445 M | $ 75.77 | -3.23 % | $ 2.13 B | ||
|
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
-33.6 M | $ 18.55 | -0.16 % | $ 122 M | ||
|
LivaNova PLC
LIVN
|
-1.15 B | $ 71.06 | 1.09 % | $ 3.88 B | ||
|
Globus Medical
GMED
|
1.39 B | $ 96.03 | -0.19 % | $ 13 B | ||
|
Medtronic PLC
MDT
|
31.5 B | $ 96.4 | -0.27 % | $ 124 B | ||
|
MiMedx Group
MDXG
|
-42.7 M | $ 5.01 | -5.02 % | $ 740 M | ||
|
Pulmonx Corporation
LUNG
|
-468 M | $ 1.59 | -2.68 % | $ 62.2 M | ||
|
Helius Medical Technologies
HSDT
|
-160 M | $ 1.93 | -11.06 % | $ 1.17 M | ||
|
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 11.47 | -1.04 % | $ 883 M |